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ABSTRACT 
Background  
Chronic musculoskeletal pain is the leading cause of disability worldwide.  The effectiveness of 
pharmacological treatments for chronic pain is often limited and there is growing concern about adverse 
effects, including opioid dependence. Non-pharmacological approaches to chronic pain may be an attractive 
alternative or adjunctive treatment.  We describe the effectiveness of a novel, theoretically-based, group 
pain management support intervention for chronic musculoskeletal pain.  
 
Methods and findings  
We conducted a multi-centre, pragmatic, randomized controlled effectiveness and cost-effectiveness (cost 
utility) trial across 27 general practices and community musculoskeletal services in the UK.  We recruited 703 
adults with musculoskeletal pain of at least 3 months duration between August 2011 and July 2012 and 
randomized, 1.33:1, to intervention (403) or control (300). Intervention participants were offered a 
participative, group intervention (COPERS) delivered over 3 alternate days with a follow up session at 2 
weeks.  The intervention introduced cognitive behavioural approaches and was designed to promote self-
efficacy to manage chronic pain.  Controls received usual care and a relaxation CD.  The primary outcome 
was pain related disability at 12 months (Chronic Pain Grade, CPG, disability subscale); secondary outcomes, 
measured at 6 and 12 months, included: Hospital Anxiety and Depression Scale (HADS) scores, Chronic Pain 
Acceptance Questionnaire; Health education impact Questionnaire Social integration subscale; Pain Self-
Efficacy Questionnaire; pain intensity (CPG subscale), the Census global health question, health utility (EQ-
5D-3L) and healthcare resource use. Analyses followed intention to treat principles, accounted for clustering 
by course in the intervention arm, and used multiple imputation for missing, or incomplete, primary 
outcome data. 
 
The mean age of participants was 59.9 years with:  81% white, 67% female, 23% in employment, 85% with 
pain for at least three years, 23% on strong opioids. Symptoms of depression and anxiety were common 
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(baseline mean HADS scores 7.4 (SD 4.1) and 9.2 (4.6), respectively). Overall 282 (70%) intervention 
participants met the pre-defined intervention adherence criterion.  Primary outcome data were obtained 
from 88% of participants.  There was no significant difference between groups in: pain related disability at six 
or 12 months (12 months: difference -1.0, intervention vs. control, 95% CI -4.9 to 3.0); pain intensity; or the 
global health question.  Anxiety, depression, pain self-efficacy, pain acceptance and social integration were 
better in the intervention group at six months; at 12 months these differences only remained statistically 
significant for depression  (-0.7, 95% CI -1.2 to -0.2) and social integration (0.8, 95% CI 10.4 to 1.2). 
Intervention participants received more analgesics than the controls across 12 months. The total cost of the 
course per person was £145 ($214). The cost utility analysis showed there to be a small benefit in terms of 
QALYs (0.0325, 95% CI: -0.0074 to 0.0724), and on the cost side the intervention was a little more expensive 
(i.e. £188 ($277), 95% CI -£125 (-$184) to £501 ($738)), resulting in an ICER of £5,786 ($8,521) per QALY.  
Limitations include the fact that the intervention was relatively brief and did not include any physical activity 
components. 
Conclusions  
The COPERS intervention was not effective for reducing pain related disability over 12 months (primary 
outcome).  For secondary outcomes, we found sustained benefits on depression and social integration at 6 
and 12 months, but there was no effect on anxiety, pain-related self-efficacy, pain acceptance, pain intensity 
or the census global health question at 12 months. There was some evidence that the intervention may be 
cost-effective based on a modest benefit on QALYs between groups. The intervention is brief, safe and 
inexpensive with a low attrition rate and has potential as a useful addition to pain management strategies.  
 
Trial registration   International Standard Randomised Controlled Trial Number Register (ISRCTN)  
registration number 24426731, http://www.controlled-trials.com/isrctn/ 
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Author Summary 
 
Why Was This Study Done?  
• Chronic pain, of which chronic musculoskeletal pain is a major component, is one of the most 
important causes of disability worldwide.  
• Pharmacological interventions are ineffective, or only partially effective, for many people with 
chronic pain and there is increasing concern about side effects (for example with non-steroidal anti-
inflammatory drugs) or drug dependence (with opioids or the gabapentinoids). 
• After systematically reviewing the evidence we developed “COPERS” - a novel, brief, psychologically 
based, group intervention directed at increasing participants’ confidence and their repertoire of skills 
around managing pain. 
• Our aim was to reduce participants’ pain related disability.  
What Did the Researchers Do and Find?  
• We conducted a large randomized control trial of the intervention; 703 participants, mostly 
identified from primary care, were randomized in a ratio of  1.33:1, to receive either the new 
intervention or usual care and a relaxation CD.   
• We followed up participants from baseline (before they were allocated to a study arm)  for 12 
months  and measured their pain related disability (our primary outcome) and a number of other 
secondary  outcomes,  including anxiety and depression and  the amount of health care resources 
they used across the 12 months.  
• The average age of the study participants was  60 years, few were in work and most (85%) had had 
pain for at least three years;  overall at baseline they reported poor health and high levels of pain 
related disability, nearly a quarter (23%) were being prescribed strong opioids.  
• The intervention had no effect on our primary outcome, pain related disability, at six or 12 months 
follow up.   The psychological outcomes were better in the group receiving the intervention 
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compared to the usual care group at six months, but by 12 months only depression and social 
integration remained improved.  
What Do These Findings Mean?  
• This study suggests that brief, group based psychological interventions are insufficient to improve 
pain related disability in with people with long-established, chronic musculoskeletal pain and 
alternative treatments are needed.  
• Anxiety and depression are common in people who have chronic pain and the study holds out the 
tantalising prospect that the new intervention could improve their psychological well-being, but 
further research is needed before this conclusion can be firmly drawn.   
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Introduction 1 
Chronic pain is common, affecting an estimated 20% [1] to 30% [2] of adults worldwide.  It is associated with 2 
disability, psychological co-morbidity, reduced quality of life, early mortality and high healthcare costs. The 3 
burden of disability due to chronic musculoskeletal disorders, commonly associated with chronic pain, 4 
increased worldwide by 46% between 1990 and 2010, with further increases predicted in coming years due 5 
to aging populations and increasing obesity [3]. In 2013 musculoskeletal disorders (combined with fractures 6 
and soft tissue injuries) accounted for over 20% of years lived with a disability across the globe [4].  Low back 7 
pain alone is the leading cause of disability in 86 countries and the second or third leading cause of disability 8 
in a further 67 countries [4]. 9 
 10 
Although pharmacological therapies have an important role in chronic pain, their effectiveness is often 11 
limited [5] and there is considerable concern about the adverse effects of non-steroidal anti-inflammatory 12 
drugs [6,7]. Many patients with chronic pain receive opioids, despite a lack of evidence around their long 13 
term effectiveness [8] and the risk of side-effects,  including dependence [9].Non-pharmacological 14 
approaches to chronic pain, such as pain management and self-management support courses that aim to 15 
improve quality of life and encourage positive behaviour change, may be an attractive alternative. There are, 16 
however, limited data to support their use. There is evidence suggesting that improving self-efficacy (an 17 
individual’s belief in their ability to succeed in a particular situation) may be a key mechanism for 18 
improvement in other outcomes [10,11] placing self-efficacy as a focus of interest for self-management 19 
interventions [12]. 20 
 21 
Based on a systematic review analysing the literature on the characteristics and effectiveness of pain 22 
management programmes [10,11], we developed a novel, theoretically underpinned, self-management 23 
support programme to improve the management of chronic musculoskeletal pain in the community and 24 
conducted a trial of this intervention: Coping with persistent Pain, Effectiveness Research into Self-25 
management study (COPERS) [14]. This programme aimed to increase self-efficacy to manage chronic pain 26 
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and attempted to address the social isolation which may accompany the experience of living with chronic 27 
pain [14]. We conceptualised the intervention within the ‘three-process model of pain’ [15], which focuses 28 
on physiological processes, subjective-affective-cognitive processes, and behavioural processes. In this 29 
model these are non-discrete, interactive processes. Hence our intervention relied on changes in 30 
understanding, mood and behaviour to enhance pain-related self-efficacy, which in turn would interact to 31 
reinforce new behaviours and impact on outcomes. We hypothesised that this new intervention would 32 
reduce pain related disability in people with chronic musculoskeletal pain. Here we describe a randomised 33 
controlled trial testing the effectiveness and cost effectiveness of the COPERS programme.  34 
 35 
Methods 36 
 37 
Study participants 38 
We conducted a pragmatic, multi-centre, randomised controlled trial of the ‘COPERS’ group self-39 
management course for adults living with chronic musculoskeletal pain. Causes of pain included, but were 40 
not restricted to, osteoarthritis, back pain, chronic widespread pain and fibromyalgia. Participants were 41 
recruited in the UK (London and the Midlands) from primary care, community musculoskeletal pain services 42 
and secondary care pain services.  The trial protocol and statistical analysis plan have been published 43 
previously [16,17]. 44 
 45 
Between August 2011 and July 2012 Potential participants were identified via electronic patient record 46 
searches [18], face to face consultation, and advertisements in clinic areas. Those who responded to initial 47 
approaches or advertisement were sent a screening questionnaire. Eligibility was subsequently confirmed in 48 
a telephone interview with a researcher, who then sent potential participants a baseline questionnaire and 49 
consent form. We included adults (aged ≥ 18 years) with musculoskeletal pain of at least three months 50 
duration [19]. Exclusion criteria were: inability to give informed consent; not fluent in English; chronic pain 51 
arising from active malignant disease or inflammatory arthritis; terminal illness; or such serious uncontrolled 52 
mental health or substance abuse issues that it would be difficult for the individual to participate in the 53 
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group sessions (this was determined by the participant’s general (family) practitioner (GP) following the 54 
electronic patient searches or at discussion between participant and researcher at the telephone interview). 55 
The trial was overseen by independent Trial Steering and Data Monitoring and Ethics committees (S1 56 
Appendix). Ethical approval was granted by Cambridgeshire Ethics Committee Ref: 11/EE/046.  57 
 58 
Randomisation 59 
Following the return of completed baseline questionnaires, participants were randomised to the two groups 60 
in a 1.33 to 1 ratio in favour of the intervention arm. Strict allocation concealment was maintained via an 61 
independent, centralised, online service which used stratified permuted blocks with randomly varying block 62 
sizes of 7 or 14 and recruitment site as a stratification factor.  63 
 64 
Outcome Measures 65 
Participants completed postal questionnaires containing the outcome measures before randomisation and 66 
at six and 12 months following randomisation. If necessary we collected primary outcomes by phone. 67 
Selection of outcome measures was based on their clinimetric qualities and informed by patient 68 
consultation. The primary outcome was pain related disability at 12 months. We chose a well-validated tool, 69 
the Chronic Pain Grade (CPG) which has two constructs—pain intensity and pain-related disability, which are 70 
scored independently and can be combined to form the Chronic Pain Grade [20]. Each construct has been 71 
validated separately [21]. The three disability subscale questions ask about pain interference with daily 72 
activities, change in ability to take part in recreational, social and family activities, and change in ability to 73 
work (including housework) over the past six months [20,21]. To generate the outcome each item is scored 74 
on a scale 0-10 (worst) and the mean is taken and multiplied by 100. This outcome has been used in a 75 
number of other trials investigating long term pain [22,23]. Secondary outcomes were: the CPG pain 76 
intensity subscale [20,21], the census global health question [20], anxiety and depression (Hospital Anxiety 77 
and Depression Scale, HADS) [25], the Chronic Pain Acceptance Questionnaire (CPAQ) [26], the Health 78 
Education Impact Questionnaire (heiQ) Social integration and support subscale [27], health utility EQ-5D-3L 79 
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[28], the Pain Self-Efficacy Questionnaire (PSEQ) [29]and health care resource use. We also examined use of 80 
psychotropic medicines, analgesics and weak and strong opioids by looking at total World Health 81 
Organisation defined daily doses (DDDs) of selected medications prescribed in the 12 months following 82 
randomisation and the proportion of participants using strong and weak opioids at 12 months follow up, full 83 
details of our outcome measures and methods are described in S2, S3 and S4 Appendices. Due to the nature 84 
of the intervention, it was not feasible to mask participants or group facilitators to study arm. Participants’ 85 
healthcare professionals and all those retrieving, handling or processing outcome data remained unaware of 86 
participants’ allocated study arms.  87 
 88 
Intervention 89 
The intervention was a group facilitated, experiential learning course based on cognitive behavioural 90 
principles plus usual care (Table 1); its development and content is described in detail elsewhere [14]. 91 
Briefly, the course consisted of 24 individual components delivered in a community setting over three 92 
alternate days in one week with a follow-up session two weeks later (total duration = 14 hours).  Content 93 
included: cognitive behavioural approaches to managing chronic pain (these covered: acceptance, attention 94 
control, goal setting and action planning, recognising unhelpful thinking and behaviours); an educational 95 
DVD with a pain consultant answering common questions from a patient with chronic pain; communication 96 
skills; relationships; hobbies and activities; posture and movement; breathing, relaxation and guided 97 
imagery. Courses were delivered by two facilitators: a health care professional with experience of treating 98 
people with chronic musculoskeletal pain (physiotherapist, psychologist, osteopath, or GP) and a lay person 99 
living with chronic pain.  Following a two day joint training programme, facilitators who met pre-determined 100 
competence criteria were selected to deliver the intervention. All courses were audio recorded and a 101 
random selection of the recordings of particular components from each course was analysed to evaluate 102 
intervention fidelity, described in detail elsewhere [30]. Participants present for at least 17 of the 24 course 103 
components were deemed ‘adherent’ to the intervention according to pre-determined criterion. 104 
Usual care  105 
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The control group received usual care, including a widely available pain education leaflet 106 
(http://www.paintoolkit.org/downloads/SC_TK_NHS_TAYSIDE.pdf), and a relaxation CD (also given to 107 
intervention participants). To mimic the duration of the intervention, control participants were asked to 108 
practise relaxation daily for three weeks and whenever they wished thereafter. 109 
 110 
Statistical Analyses  111 
To show a standardised mean difference (mean difference divided by the standard deviation at baseline) in 112 
pain related disability of 0.3 between intervention and control groups, at a 5% significance level with 80% 113 
power, would require data from 350 participants.  To minimise the overall sample size in a situation where 114 
clustering occurred only in the intervention arm (due to the group intervention), we used Moerbeek’s 115 
method, inflating the sample size by 1.37 (assuming an intra-cluster correlation coefficient of 0.1 and nine 116 
participants per course providing 12 month follow-up data) and using an unbalanced randomisation (1.33:1 117 
in favour of the intervention) [31].We required data from 480 individuals. Allowing for a 30% loss to follow-118 
up we sought to randomise 685 participants (391:294). 119 
 120 
All analyses were performed according to the intention-to-treat principle. All participants with an available 121 
outcome were analysed according to the group to which they were randomised. All analyses accounted for 122 
clustering by course in the intervention arm through use of a random-effect in a mixed-effects regression 123 
model (with participants in the control arm acting as their own cluster) [32]. Treatment group, age, gender, 124 
site of recruitment (London or Midlands)[33-35], and baseline level of outcome were included in each 125 
analysis as fixed effects [36]. 126 
 127 
We used multiple imputation for analysis of the primary outcome of pain related disability [34]. We imputed 128 
the individual questions that formed the CPG disability score, and therefore included in the imputation 129 
model and in the analysis all participants who answered at least one question on the CPG disability subscale 130 
at either 6 or 12 months. Participants who did not answer any questions on the CPG subscale at either 6 or 131 
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12 months were excluded from the analysis. We used multilevel imputation, with course included in the 132 
imputation model as a random effect. The imputation model included the three questions that formed the 133 
CPG disability score at baseline, 6 and 12 months, as well as site of recruitment, age, gender, HADS 134 
depression score at baseline, and employment status. Imputation was conducted separately within each 135 
treatment group, and 20 imputations were performed (i.e. we created 20 complete datasets). We analysed 136 
outcomes at 6 and 12 months separately, using a mixed-effects linear regression model as described above. 137 
Results were combined using Rubin’s rules [37] Analysis of secondary outcomes is described in S4 Appendix. 138 
 139 
We performed sensitivity analyses to assess robustness to different assumptions regarding the missing data 140 
(methods described in S5 Appendix). We performed the following pre-planned subgroup analyses for the 141 
primary outcome (full details in S11 Appendix): number of co-morbidities, living arrangements, baseline 142 
PSEQ score, socioeconomic status, pain duration, baseline CPG pain intensity score, baseline CPG disability 143 
score, and baseline HADS depression score. Subgroup analyses were performed by including an interaction 144 
between the specified subgroup and treatment arm in the analysis. Full details of the statistical methods can 145 
be found in the analysis plan (including details for all subgroup analyses, sensitivity analyses, and analyses of 146 
secondary outcomes) [17], which was finalised before any investigators had unmasked access to trial data. 147 
All analyses presented here were predefined in the statistical analysis plan [17] unless otherwise stated. A 148 
list of deviations from the analysis plan is available in S6 Appendix. Analysis was performed using Stata v13 149 
and REALCOM [38]. 150 
 151 
Health economic analysis  152 
The health economic analysis took a health-care provider perspective and estimated the costs of delivering 153 
the intervention and all further primary, secondary and community care costs (see S7 Appendix for more 154 
detail on methods). Service use data, including all prescribing data, were collected from participants’ GP 155 
electronic records at 12 months follow-up. Data relating to secondary care use over was downloaded from 156 
the Secondary Uses Services database [39]. Resource use data were combined with unit costs to calculate 157 
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the total cost of health service use for each participant (see S8 Appendix for unit costs). Missing data for 158 
costs and Quality Adjusted Live Years (QALYs) were imputed using Stata 12.1.The primary economic 159 
analysis was a cost-utility analysis over 12 months using QALYs calculated from the EQ-5D-3L. We used a 160 
mixed-effects linear regression model to adjust estimates of costs and QALYs for: baseline measures, 161 
treatment group, age, gender, and site of recruitment as fixed effects and course as a random effect (with 162 
participants in the control arm acting as their own cluster).  We used the non-parametric bootstrap and 163 
multiple imputations to compute cost-effectiveness acceptability curves and assessed cost-utility using 164 
willingness to pay thresholds ranging between £0 and £30,000 ($44,183). Costs were converted to US Dollars 165 
using purchasing power parity rate (2013) (http://stats.oecd.org/). 166 
 167 
Results  168 
Study participants 169 
Between August 1, 2011 and July 31, 2012 we randomised 703 participants from 35 general practices, two 170 
secondary care pain services and one community based musculoskeletal service (403:300, intervention: 171 
control)  (Figure I).  172 
--------------------------Insert Figure 1  COPERS Consort Flow chart here-------------------------------------- 173 
 174 
We over recruited to ensure the final self-management support groups at all study centres achieved the pre-175 
specified minimum number of attending participants (five). Intervention and control participants were well 176 
matched at baseline (Table 2). Most of the participants (85%) had had pain for at least three years with 265 177 
(38%) reporting pain for more than ten years and 162 (23%) being prescribed strong opioids (as defined in 178 
the British National Formulary [40]) at baseline. The median number of co-morbidities (determined from 179 
primary care records) was two (range 0-8). Only 169 (24%) were in any form of employment, with 148 (21%) 180 
unable to work due to long term sickness and another 307 (44%) who were retired. Overall health utility as 181 
assessed by the EQ-5D-3L (commonly interpreted as quality of life) was very low (mean 0.4, SD 0.34). 182 
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Eleven health care professionals and 13 lay people delivered 35 courses (the mean number of participants 184 
per course was 14). The mean waiting time from randomisation to attending a course was six weeks (range 185 
0-24 weeks); 67/403 (17%) intervention participants did not attend a course, and 282 (70%) met our pre-186 
defined definition of adherence.  187 
 188 
Pain related disability 189 
We obtained a complete set of baseline and primary outcome data from 621 (88%) participants, with 190 
multiple imputation for missing primary outcome data (see above) were able to include 652 (93%) 191 
participants in our analysis (Figure 1). Table 3 shows the results for primary and secondary outcomes at six 192 
and 12 months follow-up. Pain related disability did not differ between treatment groups at either time (12 193 
months: intervention mean 52.9 (SD 28.0) vs. control mean 53.3 (SD 28.8); difference (intervention vs. 194 
control) -1.0, 95% CI -4.9 to 3.0).  195 
 196 
Secondary outcomes 197 
 198 
At six months self-efficacy (PSEQ , difference 2.3, 95% CI 0.6 to 4.1), anxiety (HADS anxiety subscale, -0.7, 199 
95% CI -1.3 to -0.2), depression (HADS depression subscale, -0.7, 95% CI -1.2 to -0.2), pain acceptance (CPAQ, 200 
3.4, 95% CI 1.3 to 5.5) and social integration (heiQ, 0.6, 95% CI 0.1 to 1.0) had all improved more in the 201 
intervention group compared to the control group (Table 3). At 12 months the differences favouring the 202 
intervention were sustained for depression (-0.7, 95% CI -1.2 to -0.2) and social integration (0.8, 95% CI 0.4 203 
to 1.2). All sensitivity analyses found similar results to the primary analysis, demonstrating that primary 204 
outcome results were robust (see S9 Appendix for full results). 205 
 206 
There was no difference in responses to the Census global health question at 6 or 12 months follow up (odds 207 
ratio for intervention group participants being improved at 12 months was 1.07, 95% CI 0.77 to 1.51). Overall 208 
intervention patients received considerably more analgesics than controls in the 12 months following 209 
randomisation (amounting to an average difference of 98 days of medication at WHO standard dosing (95% 210 
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CI 17 to 178)). They also received significantly more weak opioids (18 DDDs, 95% CI 5 to 32 days). However 211 
there was no evidence of any difference in the prescription of strong opioids between treatment arms (-1 212 
DDD, 95% CI -12 to 11), nor in the proportions of those receiving strong opioids at 12 months (see S10 213 
Appendix for full results). 214 
 215 
Pre-specified sub-group analyses, examining subgroups based on number of co-morbidities, living 216 
arrangements, baseline PSEQ score, socioeconomic status, pain duration, baseline CPG pain intensity score, 217 
baseline CPG disability score, and baseline HADS depression score, found no differences across subgroups 218 
(full results in S11 Appendix) for the primary outcome. An exploratory post hoc sub-group analysis found 219 
that improvement in 12 month depression scores occurred only in those who were likely to be depressed at 220 
baseline (P value for interaction 0.004) (Table 4). No serious adverse events ocurred with the intervention. 221 
 222 
Health economic analyses 223 
We obtained complete health economics data from 540 participants (77%) of participants. The highest 224 
proportion of missing data was for baseline prescriptions, followed by EQ-5D-3L and primary care contacts. 225 
Imputing the data for missing values resulted in a data set of 647 participants (92%) (control n=275, 226 
intervention n=372), which represented 99% of the trial population included in the statistical analyses of the 227 
primary outcome. The cost of delivering courses, including the cost of training the facilitators was £145 228 
($214) per person. Total costs were higher in the intervention group (£2,955, $4,352) compared to the 229 
control group (£2,767, $4,075) and the difference in means was £188 ($277), 95% CI -£125 (-$184) to £501 230 
($738). Total QALYs were also higher in the intervention group (0.4475) compared to the control group 231 
(0.4150) and the difference in the means was 0.0325 (95%CI -0.0074; 0.0724) QALYs. The ICER mean point 232 
estimate was £5,786 ($8,521) per QALY. The intervention had a high probability (87%) of being cost-effective 233 
at a willingness to pay of £30,000 ($44,183) per QALY. Results of cost-effectiveness analyses are shown in 234 
S12 Appendix. 235 
 236 
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Discussion 237 
Our chronic pain self-management intervention (COPERS) was relatively cheap to deliver, and had a good 238 
uptake (336/403, 86%) with little attrition. We found no evidence of impact on our primary outcome of pain 239 
related disability at 12 months, or at six months. However at six months the COPERS intervention led to 240 
improved psychological well-being compared to the control group with regard to all our psychological 241 
measures - anxiety, depression, chronic pain acceptance and pain related self-efficacy. At 12 months the 242 
intervention arm showed continued beneficial effects on depression and social integration. These changes in 243 
health related quality of life were reflected in an incremental gain in QALYs of 0.035, a gain that was similar 244 
in size to that observed in other patient self-management programmes [41-42], and the intervention did not 245 
result in any adverse events.  The intervention was also relatively low cost, resulting in a mean costs of 246 
£5,786 ($8,521) per QALY. There is uncertainty around the estimates of costs and QALYs but when we took 247 
account of this uncertainty the intervention was shown to have a high probability (87%) of being cost 248 
effective at the current UK National Institute for Health and Care threshold of £30,000 ($44,183) per QALY 249 
[43].   250 
 251 
The finding of a long term effect on the secondary outcome of depression is of some interest. Nearly half our 252 
participants 322/703 (46%) met the criterion for possible clinical depression at baseline [44].Our observed 253 
overall effect size on depressive symptoms exceeds the effect size found in an individual patient data meta-254 
analysis of selective serotonin reuptake inhibitors for mild/moderate depression (SMD 0.11,  95% CI −0.18 to 255 
0.41), or severe depression (SMD 0.17, 95% CI −0.08 to 0.43) [45].  256 
 257 
An exploratory post-hoc analysis found a clinically significant, sustained, improvement in depressive 258 
symptoms at 12 months amongst participants with depressive symptoms at baseline; with no benefit for 259 
those who did not meet this criterion. In these post hoc analyses the SMD gain from our intervention in the 260 
group meeting the depression criterion (-0.50, 95% CI -0.74 to -0.25) is of a similar size to those reported in a 261 
network meta-analysis of large trials (≥50 per group) of psychotherapeutic  interventions for depression [46]; 262 
16 
 
Interpersonal therapy -0.73 (-1.14 to 0.32); cognitive behavioural therapy -0.47 (-0.80 to -0.35), or problem 263 
solving therapy  -0.46 (-0.81 tp-0.12); and in that reported in a Cochrane review of tricyclic antidepressants 264 
in primary care (-0.49, 95% CI -0.67 to -0.32) [47]. Notwithstanding these promising results the COPERS 265 
intervention cannot be recommended for people with depressive symptoms associated with musculoskeletal 266 
pain without evidence that this effect is found in a study including only those with depressive symptoms. 267 
 268 
The key strengths of this study were its pragmatic design, the lack of attrition and robustness of the results. 269 
We used multiple imputation to include all participants with follow-up data in the analysis, and conducted 270 
extensive sensitivity analyses to confirm the robustness of our results. Before we analysed the trial outcome 271 
we evaluated the fidelity of our intervention-this showed that it was delivered as intended [30]. 272 
 273 
Inclusion of a relaxation CD and leaflet along with usual care in the control arm might have reduced apparent 274 
effectiveness of the intervention. We chose the relaxation package because other studies had suggested that 275 
although relaxation was popular it was unlikely to have an effect on our primary outcome of pain related 276 
disability or have long term effects, but we cannot exclude the possibility that it had a therapeutic effect 277 
[15]. 278 
 279 
It not clear why participants in the intervention group were prescribed more pain killers than those in the 280 
control arm.  This finding might have arisen as a result of their gaining greater confidence or skill in 281 
communicating with their health professionals (an explicit aim of the intervention). The COPERS intervention 282 
could be more effective if it was combined with an intervention which attempted to optimise analgesic 283 
prescribing for each individual (a strategy we are currently investigating in chronic headache 284 
http://www2.warwick.ac.uk/fac/med/research/hscience/ctu/trials/other/chess/). 285 
 286 
A review and meta-analysis of mediation studies of people with back and neck pain found evidence that self-287 
efficacy, psychological distress and fear (principally fear of movement) may explain the development of 288 
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disability in people with low back or neck pain [48], although the studies were noted to be of low quality.  In 289 
our study improvements in self-efficacy and psychological distress were not accompanied by a reduction in 290 
self-reported pain related disability. It is possible that our intervention was too brief to have an effect on 291 
pain outcomes in this population who, overall, reported a long history of pain, high levels of pain related 292 
disability and low quality of life at baseline; but we were able to demonstrate a sustained effect on 293 
psychological outcomes. Most psychological interventions recognise that while improvements in pain in 294 
these patients are unlikely, improving function and well-being are paramount. Our intervention performed 295 
as well as CBT for chronic pain [49]. 296 
 297 
Improving pain related disability may require more intensive exercise based interventions, whilst this 298 
intervention was devised to encourage behaviour change for long term lifestyle change. Using this type of 299 
intervention as an adjunctive treatment may be optimal, for example with a stepped care analgesic 300 
algorithm, as for example in the SCOPE trial [50]. 301 
 302 
Although this brief intervention appears to be inexpensive and safe, and had a good uptake and low 303 
attrition, it did not improve the primary outcome of pain related disability.  The intervention’s potential to 304 
improve the psychological wellbeing of people with chronic pain, many of whom may also be anxious or 305 
depressed, could potentially benefit large numbers of people with chronic pain, but requires further 306 
research. Currently it is difficult to justify its use for those without depression and we do not know its 307 
effectiveness if only people with probable depression are included in the groups. 308 
 309 
Conclusion 310 
This novel, theoretically based intervention did not improve pain related disability in people with chronic 311 
musculoskeletal pain.  It may have a valuable role in promoting psychological well-being amongst people 312 
with chronic pain who are also anxious or depressed, but this needs further research.  Moreover, effective 313 
interventions to improve hard to shift outcomes, such as disability, in chronic pain patients are still required.314 
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Table 1 Outline of the intervention – The COPERS course 
Day Modules Content  of sessions 
1 
Living and 
dealing with 
pain 
1. Introduction and 
Understanding pain and 
acceptance 
Session 1: Introduction 
Session 2: Pain information   
Session 3: Acceptance:  The uninvited guest 
Lunch 
Taster activity – Art 
2. Mind, mood and pain Session 4: Pain, when is it bearable and when is it not?  
Session 5: The pain cycle  
3. Movement and 
Relaxation  
Session 6: Posture 
Session 7: Relaxation and breathing 
2  
Doing 
something 
about your life 
with pain 
4. Dealing with 
unhelpful, negative 
thoughts and barriers to 
change 
Session 8: Reflections from day one   
Session 9: Identifying problems, goal setting and action 
planning 
Session 10: Barriers to change - unhelpful thinking  
Lunch 
Taster activity – Hand massage 
5. Making pain more 
manageable 
Session 11: Barriers to change – reframing negatives to 
positives 
 Session 12: Attention control and distraction 
Session 13: Things that make pain more manageable 
6. Movement and 
Relaxation 
Session 14: Balance and stretch 
Session 15: Relaxation and visualisation 
3 
Communication 
and 
relationships 
 
7. Communication skills Session 16: Reflections from day 2 
Session 17: Communicating with your GP  
Session 18: Listening skills  
Session 19: Anger, irritability and frustration 
Lunch 
Taster activity – Volunteering 
8. Movement and 
Relaxation 
Session 20: Stretch 
Session 21: Relaxation and mindfulness of thoughts 
Session 22. Summary of the course 
4  
Follow up 
9. The future Session 23: Reflections and feedback from the group 
Session 24: Managing setbacks 
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Table 2 Baseline characteristics 
 
Control 
n=300Number 
(%) 
unless indicated 
otherwise 
Intervention 
n=403 
Number (%) 
unless 
indicated 
otherwise 
Number of 
Participants 
with missing 
data 
(control, 
intervention) 
Age (years) – mean (SD) 59.4 (13.8) 60.3 (13.5) 0, 0 
Male  98 (33) 132 (33) 0, 0 
Lives alone  101 (34) 143 (36) 4, 6 
Ethnicity    0, 0 
     White 239 (80) 325 (81) - 
     Black 36 (12) 53 (13) - 
     Asian 20 (7) 13 (3) - 
     Mixed/other 5 (<1) 12 (3) - 
Age at which formal education ended    0, 0 
     16 years old or less 157 (52) 224 (56) - 
     20 years old or later 135 (45) 173 (43) - 
     Other 8 (3) 6 (1) - 
Employment status    0, 0 
     Employed, including self-employed 
(full or part time) 
95 (32) 115 (29) - 
Unemployed looking for work or unable 
due to long term sickness 
72 (24) 106 (26) - 
     Retired from paid work 132 (44) 175 (43) - 
     Other 1 (<1) 7 (2) - 
Time kept from usual activities due to 
pain in past 6 months 
  3, 3 
     0-6 days 84 (28) 136 (34) - 
     7-14 days 49 (17) 72 (18) - 
     15-30 days 57 (19) 71 (18) - 
     31 or more days 107 (36) 121 (30) - 
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Control 
n=300Number 
(%) 
unless indicated 
otherwise 
Intervention 
n=403 
Number (%) 
unless 
indicated 
otherwise 
Number of 
Participants 
with missing 
data 
(control, 
intervention) 
State of healtha   0, 0 
     Very good 17 (6) 27 (7) - 
     Good 100 (33) 138 (34) - 
     Fair 130 (43) 159 (39) - 
     Bad 45 (15) 63 (16) - 
     Very Bad 8 (3) 16 (4) - 
Duration of pain    0, 0 
     0-3 months 4 (1) 1 (<1) - 
     4-12 months 10 (3) 15 (4) - 
     13 months – 2 years 43 (14) 45 (11) - 
     3-4 years 45 (15) 55 (14) - 
     5-6 years 40 (13) 49 (12) - 
     7-10 years 50 (17) 81 (20) - 
     More than 10 years 108 (36) 157 (39) - 
CPG14 overallb   3, 5 
     0 0 (0) 0 (0) - 
     1 18 (6) 30 (8) - 
     2 66 (22) 99 (25) - 
     3 81 (27) 123 (31) - 
     4 132 (44) 146 (37) - 
CPG14 disabilityc – mean (SD) 63.8 (24.4) 62.9 (25.7) 0, 1 
CPG14 pain intensityd – mean (SD) 70.9 (15.3) 71.5 (17.0) 1, 1 
PSEQ23 e – mean (SD) 30.6 (14.1) 31.2 (13.8) 0, 5 
CPAQ20 f – mean (SD) 55.3 (19.1) 57.5 (20.7) 7, 15 
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Control 
n=300Number 
(%) 
unless indicated 
otherwise 
Intervention 
n=403 
Number (%) 
unless 
indicated 
otherwise 
Number of 
Participants 
with missing 
data 
(control, 
intervention) 
HADS depression19 g – mean (SD) 7.5 (4.0) 7.4 (4.2) 3, 2 
HADS anxiety19 h – mean (SD) 9.3 (4.7) 9.2 (4.6) 3, 3 
HADS depression score19 categories   3, 2 
0 – 7 (normal) 159 (54) 217 (54)  
8 – 10 (mild) 74 (25) 95 (24)  
11 – 21(moderate or severe) 64 (22) 89 (22)  
Health education impact questionnaire 
(heiQ)21Social integration and support 
subscalei– mean (SD) 
13.8 (3.4) 14.0 (3.6) 5, 3 
EQ-5D-3L22j– mean (SD) 0.39 (0.34) 0.41 (0.34) 1, 1 
Number of co-morbiditiesk – median 
(IQR) 
3 (2 to 4) 2 (2 to 3) 21, 32 
aUK Census general health question15;bCPG Pain grades 0 (no pain)- 4(high disability, severely 
limiting pain);cCPG pain disability, mean CPG disability items scored on a scale 0-10 (worst) and 
multiplied by 100 thus 100 = worst possible score; cCPG pain intensity, mean of the three pain 
intensity CPG items scored on a scale 0-10 (worst)and multiplied by 100;  ePSEQ 0-60 (best);f 
CPAQ 0-120(best), gHADS depression0-21 (worst), hHADS anxiety0-21 (worst); iHEIQ4-20 (best), 
jEQ5D<0-1 (best),k from primary care records. 
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Table 3. Main results for primary and secondary outcomes 
 
 
Controla(n=300
) 
Interventiona(n=403
) Treatment effectb (95% CI) 
 Mean (SD) Mean (SD) Difference 
in means 
(interventio
n minus 
control) 
SMDc 
(standardise
d mean 
difference) 
Chronic Pain Grade14 
CPG disability  
    
           6 months 54.3 (26.7) 53.2 (25.7) -1.2 (-4.8 to 
2.4) 
-0.06 (-0.24 
to 0.12) 
          12 months 53.3 (28.8) 52.9 (28.0) -1.0 (-4.9 to 
3.0) 
-0.04 (-0.22 
to 0.13) 
CPG pain intensity      
           6 months 64.3 (19.4) 65.0 (18.8) 1.0 (-1.5 to 
3.6) 
0.07 (-0.10 to 
0.24) 
          12 months 64.4 (20.1) 63.5 (20.3) -0.9 (-3.7 to 
1.9) 
-0.06 (-0.23 
to 0.12) 
Pain self-
efficacyquestionnaire2
0 
PSEQ score  
    
6 months 32.7 (15.0) 35.5 (14.0) 2.3 (0.6 to 
4.1) 
0.25 (0.07 to 
0.43) 
          12 months 33.4 (15.1) 35.4 (14.1) 1.4 (-0.2 to 
3.1) 
0.15 (-0.02 to 
0.32) 
Hospital Anxiety 
Depression Scale19 
HADS Anxiety score  
    
           6 months 9.1 (4.8) 8.2 (4.7) -0.7 (-1.3 to -
0.2) 
-0.24 (-0.41 
to  
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Controla(n=300
) 
Interventiona(n=403
) Treatment effectb (95% CI) 
-0.06) 
          12 months 8.4 (4.5) 8.1 (4.5) -0.4 (-0.9 to 
0.1) 
-0.13 (-0.30 
to 0.03) 
HADS Depression 
score  
    
           6 months 7.0 (4.4) 6.3 (4.1) -0.7 (-1.2 to -
0.2) 
-0.25 (-0.44 
to  
-0.06) 
 Mean (SD) Mean (SD) Difference 
in means 
(interventio
n minus 
control) 
SMD 
(standardise
d mean 
difference) 
HADS Depression 
score  
12 months 
6.9 (4.6) 6.2 (4.3) -0.7 (-1.2 to -
0.2) 
-0.22 (-0.39 
to  
-0.06) 
Chronic Pain 
Acceptance 
Questionnaire20 
CPAQ score  
    
6 months 59.2 (19.7) 64.4 (20.0) 3.4 (1.3 to 
5.5) 
0.27 (0.08 to 
0.45) 
          12 months 74.0 (14.4) 73.1 (15.1) -0.8 (-3.0 to 
1.4) 
-0.03 (-0.20 
to 0.13) 
Health education 
impact questionnaire 
(heiQ)21Social 
integration and 
support subscale 
    
           6 months 14.3 (3.6) 14.9 (3.3) 0.6 (0.1 to 
1.0) 
0.25 (0.06 to 
0.43) 
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Controla(n=300
) 
Interventiona(n=403
) Treatment effectb (95% CI) 
          12 months 14.1 (3.6) 14.9 (3.5) 0.8 (0.4 to 
1.2) 
0.32 (0.16 to 
0.49) 
EQ-5D-3L22     
           6 months 0.41 (0.35) 0.46 (0.34) 0.03 (-0.01 
to 0.08) 
0.13 (-0.03 to 
0.29) 
          12 months 0.45 (0.35) 0.46 (0.34) 0.00 (-0.04 
to 0.04) 
0.01 (-0.16 to 
0.17) 
aMean (SD) for both treatment groups are based on raw data, i.e. are unadjusted. 
b The difference in means and the SMD were adjusted for age, gender, site of recruitment (London or 
Midlands), and baseline level of outcome.  
c SMDs were calculated using the residual SD obtained from the analysis model. 
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Table 4 Sub-group analysis* of HADS depression score at 12 months by HADS depression 
score at baseline: 0-7 vs. 8-21 
HADS depression 
score at baseline 
Control – mean 
(SD) 
Intervention – 
mean (SD) 
Treatment effect (95% 
CI) 
P-value for 
interaction 
Original scale  
0-7 4.2 (3.0) 4.0 (3.0) 0.0 (-0.7 to 0.6) 0.004 
8-21 9.4 (4.8) 8.2 (4.7) -1.5 (-2.3 to -0.8) 
Standardised mean difference 
0-7 - - -0.01 (-0.23 to 0.21) - 
8-21 - - -0.50 (-0.74 to -0.25) 
*625 participants were included in the sub-group analysis: 348 patients with HADS depression score 0-7 (148 usual care, 
200 intervention), and 277 patients with HADS depression score 8-21 (113 usual care, 164 intervention). 
